Literature DB >> 3356980

The glycoprotein of influenza C virus is the haemagglutinin, esterase and fusion factor.

G Herrler1, I Dürkop, H Becht, H D Klenk.   

Abstract

Of the biological activities of influenza C virus, haemagglutination, receptor inactivation and fusion, only the latter has been conclusively correlated with its surface glycoprotein (gp). We have purified the gp by octylglucoside treatment of influenza C virions followed by centrifugation into a sucrose gradient. Evidence was obtained that gp also represents the receptor-destroying enzyme of influenza C virus, which has been characterized as a neuraminate 9-O-acetylesterase: (i) it inactivated the receptors for influenza C virus on chicken erythrocytes; (ii) it had acetylesterase activity as indicated by the release of acetate from bovine submandibulary mucin; (iii) monoclonal antibodies directed against gp inhibited the acetylesterase activity of influenza C virus. Although purified gp was unable to agglutinate chicken red blood cells, it blocked haemagglutination by viruses. This finding as well as the haemagglutination inhibition activity of monoclonal anti-gp antibodies indicate that gp is also responsible for the haemagglutinating activity of influenza C virus. Thus, as the influenza C glycoprotein is the only myxovirus glycoprotein with three different activities, we propose the designation HEF in order to describe its function as a haemagglutinin (H), an esterase (E) and a fusion factor (F).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3356980     DOI: 10.1099/0022-1317-69-4-839

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  48 in total

1.  Attachment of mouse hepatitis virus to O-acetylated sialic acid is mediated by hemagglutinin-esterase and not by the spike protein.

Authors:  Martijn A Langereis; Arno L W van Vliet; Willemijn Boot; Raoul J de Groot
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Initial events in infectious salmon anemia virus infection: evidence for the requirement of a low-pH step.

Authors:  T M Eliassen; M K Frøystad; B H Dannevig; M Jankowska; A Brech; K Falk; K Romøren; T Gjøen
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  The hemagglutinin/esterase glycoprotein of bovine coronaviruses: sequence and functional comparisons between virulent and avirulent strains.

Authors:  X M Zhang; K G Kousoulas; J Storz
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

4.  Structure and orientation of expressed bovine coronavirus hemagglutinin-esterase protein.

Authors:  T E Kienzle; S Abraham; B G Hogue; D A Brian
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

5.  Hemagglutinin-esterase, a novel structural protein of torovirus.

Authors:  L A Cornelissen; C M Wierda; F J van der Meer; A A Herrewegh; M C Horzinek; H F Egberink; R J de Groot
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  The spike but not the hemagglutinin/esterase protein of bovine coronavirus is necessary and sufficient for viral infection.

Authors:  Rada Popova; Xuming Zhang
Journal:  Virology       Date:  2002-03-01       Impact factor: 3.616

7.  Influenza B and C virus NEP (NS2) proteins possess nuclear export activities.

Authors:  J Paragas; J Talon; R E O'Neill; D K Anderson; A García-Sastre; P Palese
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  The S protein of bovine coronavirus is a hemagglutinin recognizing 9-O-acetylated sialic acid as a receptor determinant.

Authors:  B Schultze; H J Gross; R Brossmer; G Herrler
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

9.  The E3 protein of bovine coronavirus is a receptor-destroying enzyme with acetylesterase activity.

Authors:  R Vlasak; W Luytjes; J Leider; W Spaan; P Palese
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

10.  A seven-segmented influenza A virus expressing the influenza C virus glycoprotein HEF.

Authors:  Qinshan Gao; Edward W A Brydon; Peter Palese
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.